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Role of Sp1 in the Induction of p27 Gene Expression in
Vascular Smooth Muscle Cells In Vitro and After
Balloon Angioplasty
Vicente Andrés, Jesús Ureña, Enric Poch, Donghui Chen, David Goukassian
Abstract—The abnormal proliferation of vascular smooth muscle cells (VSMCs) plays an important role in atherosclerosis
and restenosis. Although several studies have implicated the growth inhibitory protein p27Kip1 (p27) in the control of
myocyte growth and hypertrophy, little is known about the molecular mechanisms that regulate p27 expression in the
cardiovascular system. In the present study, we demonstrate the interaction of the transcription factor Sp1 with 2
GC-rich sequences within the p27 promoter in cultured VSMCs. Importantly, point mutations that disrupted Sp1 binding
markedly reduced p27 promoter activity, demonstrating that Sp1 is required for efficient p27 gene transcription in
cultured VSMCs. Because p27 expression is upregulated after balloon angioplasty, we investigated Sp1 expression and
activity in control and balloon-injured rat carotid arteries to assess the role of Sp1 as a physiological regulator of p27
expression. Although immunohistochemical analysis disclosed Sp1 protein expression in both control and balloon-
injured arteries, a high level of Sp1 DNA-binding activity was found only in response to balloon angioplasty.
Collectively, these results demonstrate that Sp1 is essential for maximum p27 promoter activity in VSMCs and suggest
that posttranslational induction of Sp1 DNA-binding activity contributes to the induction of p27 expression and VSMC
growth arrest at late time points after balloon angioplasty. (Arterioscler Thromb Vasc Biol. 2001;21:342-347.)
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Excessive vascular smooth muscle cell (VSMC) growth isinvolved in the pathogenesis of vascular proliferative
diseases, including atherosclerosis and restenosis (see re-
views1–3). With several animal models of arterial injury, it has
been shown that “activated” VSMCs resume a quiescent
phenotype within 2 to 6 weeks after angioplasty.4–8 There-
fore, a better understanding of the molecular mechanisms that
limit VSMC proliferation during the remodeling process is of
utmost importance to develop novel therapies for the treat-
ment of vascular proliferative diseases.
Cell cycle progression is controlled by several cyclin-
dependent protein kinases (CDKs), which can associate with
activating subunits, the cyclins, and with CDK inhibitory
proteins (CKIs).9,10 p27 and p21CIP1 (p21) are related CKIs
that associate with CDK2-, CDK4-, CDK6-, and CDC2-
containing complexes, thereby abrogating their catalytic ac-
tivity leading to growth arrest.9,11 Recent studies have sug-
gested a physiological role of p21 and p27 as regulators of
VSMC growth during the pathogenesis of cardiovascular
diseases (see review12). In vitro experiments have shown that
VSMC responsiveness to growth signals is highly dependent
on changes in specific components of the extracellular matrix
through a2 integrin–dependent regulation of p27 and p21.13
Reduced CDK2 activity and the decline in VSMC prolifera-
tion that takes place at late time points after angioplasty
correlated with a marked induction of p27 and p21.14–16
Moreover, overexpression of p27 efficiently blocked
mitogen- and c-fos–dependent induction of cyclin A pro-
moter activity in cultured VSMCs,15,17 and adenovirus-
mediated overexpression of p2715 and p2114,18,19 limited
neointimal thickening after balloon denudation. In contrast,
recent studies with p27 knockout mice have demonstrated
that the loss of p27 results in prolonged proliferation of
cardiac myocytes.20 Moreover, p27 plays an important role in
the regulation of cardiomyocyte hypertrophy20 and angioten-
sin II–stimulated VSMC hypertrophy.21,22
Although these studies identify p27 and p21 as important
regulators of the phenotypic response of cardiac and vascular
myocytes to mitogenic and hypertrophic stimuli, little is
known about the molecular mechanisms involved in the
regulation of CKI gene expression in the cardiovascular
system. Therefore, we investigated the transcriptional mech-
anisms that control p27 gene expression and obtained results
that demonstrate the trans-acting nuclear factor Sp1 is re-
quired for maximum p27 promoter activity in cultured
VSMCs. Moreover, using the rat carotid model of balloon
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angioplasty, we provide evidence that suggests posttransla-
tional activation of Sp1 contributes to the upregulation of p27
gene expression and the reestablishment of the quiescent
phenotype in VSMCs at late time points after vascular injury.
Methods
Cell Culture and Transient Transfection Assays
E19P cells (gift from C. Shanahan, University of Cambridge,
Cambridge, UK) were obtained from explant cultures of embryonic
day 19 aorta from Fischer rats. Through Northern blot analysis, these
cells express SM22a, calponin, and smooth muscle a-actin mRNAs
(C. Shanahan, personal communication). Cells were maintained in
M199 supplemented with 10% FBS at 37°C (95% air and 5% CO2).
Cells were seeded onto 6-well dishes, and on the next day (’60 to
80% confluence), they were transiently transfected with SuperFect
reagent (Qiagen) and 2 mg of the indicated luciferase reporter
plasmids driven by the murine p27 promoter fragments spanning
from 2170 to 154 relative to the transcriptional initiation site23 (gift
from S. Lin, National University of Singapore). To correct for
differences in transfection efficiency, luciferase activity was normal-
ized relative to the alkaline phosphatase activity produced from
cotransfected pSVAPAP plasmid (0.5 mg).24 Cells were incubated
with transfection mixtures for 90 minutes (1:2 DNA/SuperFect ratio)
and then maintained in 10% FBS/M199 for 3 days. Luciferase and
alkaline phosphatase activity was measured as previously
described.25
Balloon Angioplasty and Tissue Extraction
Male Sprague-Dawley rats (400 to 500 g) were anesthetized with an
intraperitoneal injection of sodium pentobarbital solution (45 mg/kg
body wt) for performance of balloon denudation of the left common
carotid artery in accordance with institutional guidelines as described
previously.5,26 At the indicated times after angioplasty, rats were
euthanized with sodium pentobarbital (IP injection, 100 mg/kg body
wt), and both injured and uninjured common carotid arteries were
perfused with saline through a cannula inserted into the left ventricle.
For immunohistochemistry, saline perfusion was followed by in situ
fixation with 100% methanol; then, arteries were harvested, and the
surrounding adventitia and fat tissue were carefully removed. Arter-
ies for the preparation of protein extracts and cellular RNA were
harvested without in situ fixation, cleaned of adventitia and fat tissue,
snap-frozen in liquid nitrogen, and stored at 280°C until further use
(see later).
Immunohistochemistry
Methanol-fixed arteries were embedded in paraffin and cut into
5-mm sections. Immunohistochemistry with rabbit polyclonal anti-
p27 antibodies (sc-776, 1:20 dilution; Santa Cruz Biotechnology)
and goat polyclonal anti-Sp1 antibody (sc-59-G, 1:50 dilution; Santa
Cruz Biotechnology) was performed with a biotin/streptavidin per-
oxidase detection system according to the recommendations of the
manufacturer (Signet Laboratories). Before incubation with primary
antibodies, specimens were treated with an avidin/biotin blocking
system (Signet Laboratories) to reduce nonspecific staining due to
endogenous avidin or biotin.
Preparation of Protein Extracts and
Electrophoresis Mobility Shift Assays
Cells and arteries were lysed in ice-cold buffer that contained
20 mmol/L HEPES buffer, pH 7.5, 10 mmol/L EGTA, 40 mmol/L
b-glycerophosphate, 1% NP-40, 2.5 mmol/L MgCl2, 2 mmol/L
orthovanadate, 1 mmol/L DTT, 1 mmol/L PMSF, 10 mg/mL apro-
tinin, and 10 mg/mL leupeptin. Protein extracts were prepared from
the pooled tissue from 7 to 9 animals at each time point. Lysates
were cleared with centrifugation in a microfuge, and the supernatants
were stored at 280°C. Western blot analysis with mouse monoclonal
anti-p27 antibody (Ab-2, dilution 1:75; Oncogene) was performed
with an ECL detection system (Amersham).
The following radiolabeled probes that span the murine p27
promoter regions from 2140 to 2109 and from 2101 to 272 and
contain 2 GC-rich boxes (box I 2133 to 2117, box II 287 to 272)
were used for electrophoresis mobility shift assays (EMSAs) (bind-
ing sites are underlined, and point mutations are given in lowercase
letters): box I (wild-type), 59-GCGCGGAGAGCGGCGGCGCC-
GCGCCCCGGGCC-39; box I (mutant), 59-GCGCGGAGAGCGaa-a
GCGCaaaGCCCCGGGCC-39; box II (wild-type), 59-GAGCG-
CGCTCGCCAGCCTGGGCGGAGCGGC-39; and box II (mutant),
59-GAGCGCGCTCGCCAGCCTGaaaGGAGCGGC-39.
Other probes used in these studies included the consensus Sp1
(59-ATTCGATCGGGGCGGCGAGC-39) and AP1 (59-CGCT-
TGATGAGTCAGCCGGAA-39) binding sites. EMSA was per-
formed as previously described.17 To demonstrate the presence of
Sp1 in the retarded nucleoprotein complexes, cell extracts were
preincubated for 20 minutes with 3 mg of mouse monoclonal
anti-Sp1 antibody (sc-420X; Santa Cruz Biotechnology) before
addition of the probe.
Northern Blot Analysis
Arterial total RNA from control and balloon-injured rats was isolated
from the pooled tissue from 3 animals with Tri-Reagent according to
the recommendations of the manufacturer (GIBCO BRL). Ten
micrograms of RNA was electrophoresed on 1% agarose gels that
contained 2.2 mol/L formaldehyde, transferred to nylon membranes
(Hybond-N; Amersham), and immobilized by short-wave UV irra-
diation (UV-Stratalinker 1800; Stratagene). Blots were hybridized
with radiolabeled cDNA probes for p27 and GAPDH. Autoradio-
graphs were scanned (Microtek Scan Maker II), and band intensity
was determined after background subtraction with the densitometric
program Sigma Gel (Jandel Scientific).
Results
Sp1 Interacts With Two GC-Rich Sequences
Within the p27 Gene Promoter That Are Required
for Maximum Transcriptional Activity in VSMCs
Analysis of the proximal promoter region of the murine p27
gene revealed 2 GC-rich regions (box I 2133 to 2117, box
II 287 to 272), which are putative binding sites for the
transcription factor Sp1. As shown in the EMSA in Figure
1A, the incubation of E19P cell extracts with the box II probe
leads to the formation of a slow migrating nucleoprotein
complex (lane 2), which was disrupted when an excess of
unlabeled wild-type box II oligonucleotide was added to the
binding reaction (lane 3). A mutated box II oligonucleotide
that disrupted the putative Sp1 binding site did not compete
for binding (Figure 1A, lane 4), demonstrating the require-
ment of the GC-rich motif for nucleoprotein complex forma-
tion. Two additional faster migrating bands that could not be
disrupted with either wild-type or mutated box II oligonucle-
otides corresponded to nonspecific interactions (Figure 1A,
NS). Although less intense compared with autoradiographs
with box II probe, a retarded band of the same electrophoretic
mobility was seen with the box I probe (data not shown).
A series of experiments were then performed to demon-
strate the interaction of Sp1 with these GC-rich motifs within
the p27 proximal promoter region. First, the electrophoretic
mobility of the specific complex detected with the wild-type
box II probe was identical to that observed with a probe
containing an Sp1 consensus site (Figure 1A, compare lanes
2 and 7). Similar results were obtained with the wild-type box
I probe (data not shown). Moreover, the DNA-binding
specificity of the factor bound by box I, box II, and the Sp1
consensus probes was indistinguishable on the basis of
cross-competition experiments. Although both wild-type box
I and box II efficiently competed for binding to the Sp1
consensus probe (Figure 1B, lanes 3 to 5 and 9 to 11), their
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mutant versions did not affect binding under the same
conditions (Figure 1B, lanes 6 to 8 and 12 to 14). Likewise,
the Sp1 consensus oligonucleotide was very efficient at
disrupting the nucleoprotein complex seen with box I (data
not shown) and box II (Figure 1A, lane 5) probes. Finally, the
addition of an anti-Sp1 antibody disrupted the binding activ-
ity detected with both the Sp1 consensus and box II probes
(Figure 1C), demonstrating the presence of Sp1 in these
nucleoprotein complexes.
Having demonstrated the binding of Sp1 to the p27
promoter in cultured VSMCs, we investigated the functional
consequences of this interaction. To this end, E19P cells were
transiently transfected with luciferase reporter genes driven
by the p27 gene promoter. As shown in Figure 2, the
wild-type p27 promoter fragment from 2170 to 154 acti-
vated reporter gene expression. Importantly, point mutations
that disrupted the binding of Sp1 to box I and box II reduced
promoter activity by 65% compared with the corresponding
wild-type fragment. Collectively, these experiments demon-
strated that Sp1 interacts with 2 GC-rich motifs within the
p27 gene promoter that are required for maximum transcrip-
tional activity in cultured VSMCs.
Sp1 and p27 Spatial and Temporal Pattern of
Expression After Balloon Angioplasty
To assess the role of Sp1 as a physiological regulator of p27
expression in vivo, we investigated the spatial and temporal
patterns of expression of these factors in control and balloon-
injured rat carotid arteries. VSMC proliferation in this model
of vascular injury peaks during the first week and then
declines thereafter to return to baseline levels within 2 to 3
weeks.5,6,27 In agreement with previous studies that reported
the induction of p27 in balloon-injured arteries,15,16 immuno-
histochemical analysis disclosed elevated p27 protein expres-
sion at 10 days after balloon angioplasty, which was main-
tained at 2 weeks after injury (Figure 3). Western blot
analysis was more sensitive and revealed expression of p27 in
uninjured vessels that was induced between 1 to 2 weeks after
angioplasty (Figure 4A). Moreover, averaged over 2 indepen-
dent experiments, Northern blot analysis disclosed a 3.5-fold
induction of p27 steady-state mRNA level at 2 weeks after
angioplasty compared with uninjured arteries (Figure 4B).
Immunohistochemical analysis revealed abundant expres-
sion of Sp1 in both control and balloon-injured carotid
arteries (Figure 3). Importantly, lower p27 mRNA and
protein expression in uninjured arteries and up to 2 days after
angioplasty correlated with lower Sp1 DNA-binding activity
(Figure 4C, lanes 2 to 4). By day 5 after angioplasty, Sp1
DNA-binding activity was markedly induced and remained
elevated until day 18 (Figure 4C, lanes 5 to 7). The specificity
of the nucleoprotein complex was demonstrated by the ability
of unlabeled homologous oligonucleotide (lanes 8 to 13), but
not unrelated AP1 oligonucleotide (lanes 14 and 15), to
compete for binding.
Previous studies demonstrated a rapid induction in the
expression and activity of AP1 transcription factors after
balloon angioplasty, suggesting that early proto-oncogene
expression contributes to injury-induced VSMC prolifera-
tion.17,28,29 Consistent with these findings, and in contrast to
the temporal pattern of Sp1 DNA-binding activity, maximum
Figure 1. Sp1 interacts with 2 GC-rich sequences
within the p27 gene promoter. E19P cells lysates
(20 mg total protein) were incubated in binding
reactions with radiolabeled probes containing a
consensus Sp1 binding site (Sp1 cons) or the
GC-rich box located at position 282 to 272 (box
II) within the murine p27 promoter (see Methods).
A, EMSA was performed with box II (lanes 1 to 5)
and Sp1 cons (lanes 6 to 8) probes. Competition
experiments were carried out with a 50-fold excess
of unlabeled oligonucleotides. Lanes 1 and 6 show
control reactions without cell lysate. Nonspecific
bands that could not be disrupted with competi-
tors are indicated (NS). B, EMSA was performed
using the Sp1 consensus probe. A 50-fold excess
of unlabeled Sp1 oligonucleotide competed for
binding. Increasing amounts of wild-type box II and box I (position 2133 to 2117 within the murine p27 promoter) also disrupted bind-
ing. In contrast, mutated box I and box II did not compete under the same conditions. The amount of competitor was 150-fold (lanes 3,
6, 9, and 12), 250-fold (lanes 4, 7, 10, and 13), and 500-fold (lanes 5, 8, 11, and 14). C, Preincubation of cell extracts with monoclonal
anti-Sp1 antibody inhibited binding to the box II and Sp1 consensus probes. Nonspecific bands are indicated (NS).
Figure 2. Sp1 binding sites are required for maximum p27 pro-
moter activity in VSMCs. E19P cells were transiently transfected
with luciferase reporter genes driven by fragments of the murine
p27 gene promoter spanning from 2170 to 154 relative to the
transcriptional initiation site. WT indicates wild-type promoter
fragment; box I1II mutant, point mutations disrupting the 2
GC-rich boxes located at positions 2133 to 2117 (box I) and
287 to 272 (box II). The mutations in the box I1II mutant are
identical to those of the mutated oligonucleotides used for
EMSA (see Methods). To correct for differences in transfection
efficiency, luciferase activity was normalized relative to the level
of alkaline phosphatase activity produced from cotransfected
pSVAPAP plasmid. Results represent the mean6SEM of 3 inde-
pendent transfections.
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AP1-DNA–binding activity was induced shortly after balloon
angioplasty and then declined at later time points (Figure 4D,
lanes 2 to 7). Unlabeled AP1 oligonucleotide (Figure 4D,
lanes 8 to 13), but not unrelated Sp1 oligonucleotide (Figure
4D, lanes 14, 15), competed for binding to the AP1 consensus
probe, demonstrating the specificity of the nucleoprotein
complex. These results reveal striking differences between
the temporal and spatial patterns of expression and activity of
AP1 and Sp1 proteins in the arterial wall.
Discussion
High levels of the CKIs p21 and p27 have been found in
VSMCs at later phases of arterial remodeling that correlated
with reduced CDK2 activity and the decline in VSMC growth
that takes place after the initial burst of proliferation.14–16
Thus, the upregulation of p21 and p27 may contribute to
VSMC growth arrest at late time points after angioplasty. In
agreement with this hypothesis, adenovirus-mediated overex-
pression of p2114,18,19 and p2715 attenuated neointimal thick-
ening in balloon-injured arteries. Despite all of these findings
that implicate p21 and p27 as inhibitors of VSMC prolifera-
tion, little is known about the molecular networks that
regulate CKI expression during arterial remodeling in vivo.
The purpose of the present study was to elucidate regula-
tory mechanisms that control p27 gene expression in VSMCs
in vitro and in the setting of balloon angioplasty. Our EMSAs
demonstrated the interaction of the trans-acting factor Sp1
with 2 GC-rich regions within the p27 proximal promoter
region. Moreover, maximum transcription from the p27
promoter was markedly reduced when VSMCs were tran-
siently transfected with reporter genes harboring point muta-
tions that disrupted both Sp1 binding sites. Although these
results suggested that Sp1 is an important regulator of p27
gene expression in cultured VSMCs, the induction of p27
mRNA and protein expression after balloon angioplasty of
the rat carotid artery did not correlate with changes in Sp1
protein expression. Importantly, a lower level of Sp1 DNA-
binding activity was found in uninjured arteries and during
the early time points after angioplasty, when p27 expression
is lower and maximum VSMC proliferation is detected.
Consistent with a role of Sp1 as a transcriptional activator of
p27 in balloon-injured arteries, elevated p27 expression at
late time points during vascular remodeling correlated with a
Figure 3. Immunohistochemical localization
of Sp1 and p27 in control and balloon-
injured rat carotid arteries. Arterial cross-
sections were incubated with goat poly-
clonal anti-Sp1 (left) and rabbit polyclonal
anti-p27 (right) antibodies. Photomicro-
graphs of Sp1 and p27 localization at each
time point correspond to the same region
from 2 consecutive sections. Immunocom-
plexes were detected with a biotin/streptavi-
din peroxidase system. AEC substrate was
used to detect p27 in uninjured arteries, and
DAB substrate was used in the remainder of
the specimens. Arrowheads indicate the
external (black) and internal (white) elastic
laminae.
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marked induction of Sp1 DNA-binding activity. Therefore,
posttranslational induction of Sp1 in the injured vessel wall
may contribute to transcriptional activation of p27 gene
expression and the cessation of VSMC proliferation at later
phases during arterial remodeling. However, we cannot rule
out the possibility that increased mRNA stability plays an
important role in the upregulation of steady-state p27 mRNA
levels in the injured arterial wall. It is also noteworthy that
induction of Sp1 DNA-binding activity at 5 days after injury
preceded the upregulation of p27 gene expression, suggesting
that another factor or factors independent of Sp1 are neces-
sary for maximum p27 gene expression in vivo. In this
regard, we have shown that activity of the box I1II mutant
reporter gene was reduced to 35% of that seen with the
wild-type promoter; however, these mutations did not abolish
p27 promoter activity (Figure 2). Thus, although these results
suggest that Sp1 plays an important role as a transcriptional
activator of p27 gene expression, additional factors appear to
be required for maximum p27 gene transcription.
Our immunohistochemical studies suggested distinct reg-
ulation of Sp1 expression in medial and neointimal VSMCs.
Sp1 immunoreactivity was high within the neointima at all
time points analyzed, but expression of Sp1 in medial
VSMCs was low up to 10 days after angioplasty compared
with uninjured vessels or 2 weeks after angioplasty. Thus,
future studies should address whether Sp1 expression and
DNA-binding activity are regulated during phenotypic mod-
ulation of VSMCs and the molecular mechanisms that under-
lie this regulation.
Our results with cultured VSMCs and balloon-injured
arteries extend previous studies that demonstrate binding of
Sp1 to both of the GC-rich motifs in the proximal p27 gene
regulatory region is required for p27 promoter activity in
cancerous human HeLa and U937 cells.23,30 Likewise, several
studies have demonstrated that Sp1 binds specifically to
oligonucleotides that correspond to Sp1-like motifs clustered
within the proximal p21 promoter region31–33 and that this
interaction is essential for constitutive p21 promoter activity
in transiently transfected human hepatoma HepG2 cells.34 In
vitro studies with different cell types have shown that
inducible p21 gene transcription also requires functional Sp1
binding sites; these include the induction of p21 promoter by
nerve growth factor in PC12 pheochromocytoma cells,35 by
fumonisin B1 in CV1 cells,33 by transforming growth
factor-b in HaCaT human keratinocytes,31 and by phorbol
esters and okadaic acid in U937 human leukemic cells.32
Collectively, these studies implicate Sp1 as a physiological
regulator of CKI gene expression in several cell types and
pathophysiological processes. In contrast to the response to
vascular injury, where p27 upregulation may limit patholog-
ical VSMC proliferation, reduced expression of p27 in
several human cancers appears to correlate with neoplastic
growth and poor patient survival rates.36–39 In this context, it
will be interesting to determine whether reduced Sp1 expres-
sion, function, or both may play a role in the inhibition of p27
gene expression during neoplastic growth.
In conclusion, we show here that Sp1 is required for
maximum p27 gene transcription in VSMCs via its interac-
tion with 2 GC-rich sequences within the p27 promoter.
Using the rat carotid model of balloon angioplasty, we
provide evidence that Sp1 may contribute to inducible p27
expression in vivo. Given that Sp1 is also an important
transcriptional activator of p21, it is tempting to speculate that
elevated Sp1 DNA-binding activity in the injured arterial wall
contributes to p27 and p21 upregulation, which may in turn
promote VSMC growth arrest at later phases during the
vascular response to balloon denudation. The observation that
Sp1 protein is expressed in uninjured arteries, which dis-
closed lower Sp1 DNA-binding activity, suggests that its
induction after angioplasty is likely mediated by a posttrans-
lational modification of Sp1. These results illustrate a link
between the transcriptional and cell cycle machinery that may
be relevant to the pathogenesis of vascular proliferative
disorders.
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